S. Megnien

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

Stephen Harrison, Vlad Ratziu, Jérôme Boursier et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 243 citations

Medicine, Internal Medicine, Pathology +16

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

Jörn M. Schattenberg, Albert Parés, Kris V. Kowdley et al. · Journal of Hepatology · 2021 · 178 citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Mohammad Shadab Siddiqui, Stephen A. Harrison, Manal F. Abdelmalek et al. · Hepatology · 2017 · 167 citations · Full text

Medicine, Internal Medicine, Clinical Research Regulation +13

35th Annual Meeting of the European Association for the Study of Diabetes

Arne Melander, Jonny Olsson, Gunnar Lindberg et al. · Diabetologia · 1999 · 86 citations

Medicine, Endocrinology, Internal Medicine +11